E-selectin ligand-1 (ESL-1) is a novel adiponectin binding protein on cell adhesion

Yamamoto, Hiroyasu; Kuroda, Nana; Uekita, Hiromi; Kochi, Ikoi; Matsumoto, Ayaka; Niinaga, Ryu; Funahashi, Tohru; Shimomura, Iichiro; Kihara, Shinji

doi:10.1016/j.bbrc.2016.01.023

Cited by 9 publications

(7 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One possibility is that at these concentrations, sSiglec-5/Fc also interferes with the adhesion of another P-selectin ligand. A potential candidate is ESL-1, which is expressed on THP1-cells and it binds to P-selectin in a glycan-dependent manner2829. The specificity of sSiglec-5/Fc was not limited to THP1-cells, but this soluble protein also reduced rolling of primary leukocytes, both PBMCs and PMNs (Fig.…”

Section: Discussionmentioning

confidence: 99%

Soluble Siglec-5 associates to PSGL-1 and displays anti-inflammatory activity

Pépin

Mezouar

Pegon

et al. 2016

Sci Rep

View full text Add to dashboard Cite

Interactions between endothelial selectins and the leukocyte counter-receptor PSGL1 mediates leukocyte recruitment to inflammation sites. PSGL1 is highly sialylated, making it a potential ligand for Siglec-5, a leukocyte-receptor that recognizes sialic acid structures. Binding assays using soluble Siglec-5 variants (sSiglec-5/C4BP and sSiglec-5/Fc) revealed a dose- and calcium-dependent binding to PSGL1. Pre-treatment of PSGL1 with sialidase reduced Siglec-5 binding by 79 ± 4%. In confocal immune-fluorescence assays, we observed that 50% of Peripheral Blood Mononuclear Cells (PBMCs) simultaneously express PSGL1 and Siglec-5. Duolink-proximity ligation analysis demonstrated that PSGL1 and Siglec-5 are in close proximity (<40 nm) in 31 ± 4% of PBMCs. In vitro perfusion assays revealed that leukocyte-rolling over E- and P-selectin was inhibited by sSiglec-5/Fc or sSiglec-5/C4BP, while adhesion onto VCAM1 was unaffected. When applied to healthy mice (0.8 mg/kg), sSiglec-5/C4BP significantly reduced the number of rolling leukocytes under basal conditions (10.9 ± 3.7 versus 23.5 ± 9.3 leukocytes/field/min for sSiglec-5/C4BP-treated and control mice, respectively; p = 0.0093). Moreover, leukocyte recruitment was inhibited over a 5-h observation period in an in vivo model of TNFalpha-induced inflammation following injection sSiglec-5/C4BP (0.8 mg/kg). Our data identify PSGL1 as a ligand for Siglec-5, and soluble Siglec-5 variants appear efficient in blocking PSGL1-mediated leukocyte rolling and the inflammatory response in general.

show abstract

Section: Discussionmentioning

confidence: 99%

Soluble Siglec-5 associates to PSGL-1 and displays anti-inflammatory activity

Pépin

Mezouar

Pegon

et al. 2016

Sci Rep

View full text Add to dashboard Cite

show abstract

“…ESL-1 is a membrane protein on monocytes involved in the initiation of atherosclerosis through the binding to vascular endothelial E-selectin. Therefore, APN inhibits monocyte adhesion to the vascular endothelium by interfering with the binding between ESL-1 and E-selectin, which could be an anti-atherosclerotic mechanism of APN 22) . Originally, we found that APN decreased the TNF--stimulated expression of adhesion molecules on vascular endothelial cells 40) .…”

Section: Discussionmentioning

confidence: 99%

“…Recently, we determined several APN-interacting molecules, E-selectin ligand-1 (ESL-1) 22) , cystatin C (CysC) 23) , and Mac-2 binding protein (M2BP) 24) , and we demonstrated that the functions of APN and its interacting molecules are mutually regulated. Moreover, the possible interaction between APN and several chemokines was suggested in a previous report 25) .…”

Section: Introductionmentioning

confidence: 99%

Atheroprotective Roles of Adiponectin via CCL2 Inhibition

Fujita

Yamamoto

Yoshida

et al. 2021

JAT

Self Cite

View full text Add to dashboard Cite

Aim: Adiponectin (APN) exhibits different atheroprotective effects, and we have previously reported that APN function is modulated by its binding proteins, E-selectin ligand 1, Mac-2 binding protein, and cystatin C. In the present study, we aimed to identify a novel atheroprotective mechanism of APN via C–C motif chemokine 2 (CCL2). Methods: We conducted iMAP ® -intravascular ultrasound (IVUS) in 111 Japanese male patients with stable angina. The plaque characteristics were determined where “plaque burden” [(EEM CSA − lumen CSA)/(EEM CSA)×100 (%)] ＞50%, and their correlation with serum CCL2 and APN levels was analyzed. Using western blot analysis, the effects of APN on the biological effects of CCL2 were examined in their mutual binding by co-immunoprecipitation assay, the monocyte migration, and the phosphorylation of MAP kinases. Results: In a clinical study, we found that the percentage of plaque in the culprit lesion was correlated positively with serum CCL2 and negatively with serum APN levels, with significance. We identified CCL2 as a novel APN-binding serum protein using immunoprecipitation and western blot analysis. CCL2-induced phosphorylation of MAP kinases and monocyte migration was significantly attenuated by APN in vitro . Conclusion: The opposite association of APN and CCL2 on the percentage of coronary plaque might be caused by their direct interaction and competitive functions on monocyte migration.

show abstract

“…Transfection, immunoprecipitation, and immunoblotting were performed as described previously 20 , 22 ) . Briefly, 100 µg mouse anti-human APN monoclonal antibody (ANOC9121; Otsuka Pharmaceutical Co., Ltd., Tokyo, Japan) or mouse control immunoglobulin G (IgG) was coupled to 5 mg tosylactivated Dynabeads ® (M-280; Invitrogen, Carlsbad, CA), according to the manufacturer's instructions.…”

Section: Methodsmentioning

confidence: 99%

“…We have demonstrated that proteins interacting with APN (e.g., platelet-derived growth factor-BB, calreticulin, cystatin C (CysC), E-selectin ligand-1, and Mac-2 binding protein) modulate APN-mediated vasculoprotective effects 18 – 22 ) . CysC is a cysteine protease inhibitor that is constantly produced by human cells in general and excreted into the bloodstream 23 ) .…”

Section: Introductionmentioning

confidence: 99%

Cystatin C–Adiponectin Complex in Plasma Associates with Coronary Plaque Instability

Matsumoto

Yamamoto

Matsuoka

et al. 2017

JAT

Self Cite

View full text Add to dashboard Cite

Aim: Adiponectin (APN) is an adipocyte-derived bioactive molecule with antiatherogenic properties. We previously reported that cystatin C (CysC) abolished the anti-atherogenic effects of APN. We aimed to elucidate the clinical significance of CysC–APN complex in patients with coronary artery disease (CAD).Methods: We enrolled 43 stable CAD male patients to examine the relationship between CysC–APN complex and coronary plaque characteristics. Serum was immunoprecipitated by the anti-APN antibody and immunoblotted by the anti-CysC antibody to demonstrate the presence of CysC–APN complexes in vivo. To confirm their binding in vitro, HEK293T cell lysates overexpressing myc-APN and FLAG-CysC were immunoprecipitated with an anti-myc or anti-FLAG antibody, followed by immunoblotting with an anti-APN or anti-CysC antibody.Results: CysC was identified as a specific co-immunoprecipitant with APN by the anti-APN antibody in human serum. In vitro, FLAG-CysC was co-immunoprecipitated with myc-APN by the antimyc antibody and myc-APN was co-immunoprecipitated with FLAG-CysC by the anti-FLAG antibody. Among CAD patients, serum CysC–APN complex levels negatively correlated with fibrotic components of coronary plaques and positively correlated with either necrotic or lipidic plus necrotic components. Plaque burden negatively correlated with serum APN levels but not serum CysC–APN complex levels. Serum CysC levels had no association with plaque characteristics. In multivariate analysis, CysC–APN complex levels were identified as the strongest negative factor for fibrotic components and the strongest positive factor for both necrotic and lipidic plus necrotic components.Conclusion: Measuring serum CysC–APN complex levels is helpful for evaluating coronary plaque instability in CAD patients.

show abstract

E-selectin ligand-1 (ESL-1) is a novel adiponectin binding protein on cell adhesion

Cited by 9 publications

References 35 publications

Soluble Siglec-5 associates to PSGL-1 and displays anti-inflammatory activity

Soluble Siglec-5 associates to PSGL-1 and displays anti-inflammatory activity

Atheroprotective Roles of Adiponectin via CCL2 Inhibition

Cystatin C–Adiponectin Complex in Plasma Associates with Coronary Plaque Instability

Contact Info

Product

Resources

About